CG On­col­o­gy aims for $181M list­ing in first biotech IPO of 2024

CG On­col­o­gy ap­pears poised to be the first biotech IPO of 2024 as it dis­closed Thurs­day morn­ing it will seek about $181 mil­lion in its Nas­daq de­but.

The pro­posed list­ing comes as in­vestors and in­dus­try in­sid­ers breathe an air of op­ti­mism with pos­i­tive mo­men­tum from De­cem­ber and a sun­shine cleanse at the JP Mor­gan Health­care Con­fer­ence last week.

CG’s jump to Wall Street could al­so serve as a bell­wether for the first quar­ter of IPOs as five oth­er biotechs are in the queue: late-stage on­col­o­gy start­up Ar­riVent Bio­phar­ma, Phase II Al­to Neu­ro­science, pre­clin­i­cal gene edit­ing com­pa­ny Metageno­mi, obe­si­ty gene ther­a­py mak­er Fractyl Health and mid-stage au­toim­mune CAR-T mak­er Kyver­na Ther­a­peu­tics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER